Terminal sterilisation is the application of a lethal process to a medicinal product in its final sealed container. The sterility assurance level describes the resulting probability that a viable microorganism remains after the process; for terminal sterilisation, Annex 1 specifies a level of 10^-6 or better.
Probability rather than absolute sterility
A sterilisation process cannot be characterised by claiming absolutely measurable sterility. The sterility assurance level is therefore a probabilistic expression: a value of 10^-6 means that the theoretical probability of a surviving microorganism is at most one unit in one million. This statement assumes that the initial bioburden, process parameters and validation model are under control.
In terminal sterilisation, the product is already in its final container. The validated cycle must therefore not only kill microorganisms, but also reflect the actual transfer of heat or radiation through the product, packaging components and load. Cold spots, loading patterns and the worst-case configuration determine where process performance must be demonstrated.
Validation of the lethal process
The appropriate method depends on the product and container. Steam, dry heat, ionising radiation, ethylene oxide or other methods have different mechanisms of action and different risks for the material and the medicinal product. Before selection, it is assessed whether the active substance, formulation and container can tolerate the exposure without unacceptable quality changes.
Validation combines physical measurements with microbiological considerations. Temperature or dose distribution shows whether process conditions were achieved at all relevant points. For biological indicators and D-values, consideration is given to how resistant a reference organism is to the selected method. The aim is a justified, reproducible lethal effect within defined limits. For sterile investigational medicinal products, the detailed Commission guideline C(2017) 8179 final states that validation of sterilisation processes follows the same standards as for authorised medicinal products and that the principles of Annex 1 must be taken into account; Article 9(3) of Commission Delegated Regulation (EU) 2017/1569 explicitly identifies sterilisation as a process stage that is essential for the safety of trial subjects and therefore must be validated and regularly revalidated.
The initial bioburden influences how a cycle is designed and interpreted. It is not viewed as a mere average figure, but in relation to raw materials, manufacturing time, intermediate storage and the method’s ability to reliably control a high bioburden. A subsequently increased bioburden can reduce the assumed safety margin, even though the programmed time and temperature values remain unchanged.
Demonstrating heat distribution alone is not sufficient if the product significantly alters heat transfer. For viscous solutions, large fill volumes or specific container geometries, it is investigated which location within the product experiences the slowest heating. This location is usually more relevant for microbiological efficacy than the displayed value in the steriliser chamber.
After maintenance, a change in loading, or replacement of a packaging component, it is assessed whether the validated configuration is still valid. The sterility assurance level therefore does not belong as a fixed number on a label, but to the controlled state of a specific process.
Distinction from overkill sterilisation and aseptic manufacturing
Overkill sterilisation is a specific validation approach within terminal sterilisation. Annex 1 defines it as a method with at least twelve logarithmic reduction steps at a D-value of at least one minute. It is therefore based on an explicitly large safety margin against a defined microbiological load.
If a product cannot be terminally sterilised, aseptic manufacturing may be required. In that case, sterility is not achieved by a lethal step in the sealed final container, but through sterile components, a controlled environment and aseptic processing. Aseptic process simulation assesses this different control logic, whereas the sterility assurance level for terminal sterilisation quantifies the performance of the lethal cycle.
Routine monitoring confirms that the released cycle was run within its specified parameters. It must be distinguished from initial validation, which demonstrates the fundamental suitability of this cycle.
For each release, it must be traceable which load was actually sterilised and whether it falls within the validated range. Deviating loads are not considered equivalent solely because an indicator result passed.
Relevance for clinical trials
For sterile investigational medicinal products, the decision between terminal sterilisation and aseptic manufacturing affects the entire manufacturing plan. For a new formulation, data on product stability after the sterilisation process, the configuration of the clinical packaging and the manufacturing site’s capacity must align. A change in the container or fill volume can call the transferability of an existing sterilisation cycle into question.
Full-service CROs such as Mediconomics provide support by coordinating CMC data, clinical packaging planning and regulatory documentation for the chosen sterilisation strategy. When preparing the release of clinical batches, they can align the required evidence on cycle, load, deviations and stability with the study’s delivery timelines.
Frequently asked questions (FAQ)
Is a sterility assurance level of 10^-6 a measured value for each individual batch?
No. It is the result of a validated process concept and its parameters. The individual batch is manufactured and documented within this validated framework.
Why is the final container important for terminal sterilisation?
Because packaging components, fill volume and loading influence whether the required sterilisation effect is achieved at the worst-case location. These factors are part of validation.
Can a finished-product sterility test replace the sterilisation cycle?
No. The test examines only a limited sample; it cannot fully represent the spatial and temporal performance of a validated sterilisation process.
Regulatory References
- EudraLex Volume 4, Annex 1 “Manufacture of Sterile Medicinal Products” — defines terminal sterilisation, sterility assurance level and overkill sterilisation.
- Detailed Commission guideline C(2017) 8179 final — requires the same validation standard for sterile investigational medicinal products as for authorised medicinal products.
- Commission Delegated Regulation (EU) 2017/1569 — sets out GMP principles for investigational medicinal products and their batch consistency.